Refine
Has Fulltext
- yes (18)
Is part of the Bibliography
- yes (18) (remove)
Year of publication
Document Type
- Journal article (16)
- Doctoral Thesis (2)
Keywords
- crystal structure (18) (remove)
Institute
- Institut für Anorganische Chemie (7)
- Julius-von-Sachs-Institut für Biowissenschaften (3)
- Rudolf-Virchow-Zentrum (3)
- Institut für Pharmazie und Lebensmittelchemie (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Graduate School of Life Sciences (1)
- Institut für Molekulare Infektionsbiologie (1)
- Institut für Pharmakologie und Toxikologie (1)
- Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
Aufklärung der Struktur und Charakterisierung des ternären Komplexes aus BMP-2, BMPR-IA und ActR-IIB
(2006)
„Bone Morphogenetic Proteins“ (BMPs) kontrollieren eine Vielzahl unterschiedlichster Prozesse bei der Embryonalentwicklung und der postnatalen Gewebehomöostase. Wie TGF-betas, Activine und andere Mitglieder der TGF-beta Superfamilie vermitteln BMPs ihr Signal durch die Bildung eines aus dem Liganden und zwei Rezeptorsubtypen bestehenden Signalkomplexes. Für die Rezeptoraktivierung ist ein Zwei-Schritt Mechanismus allgemein akzeptiert. Bisher wurde nur der erste Schritt, die Bindung des Liganden an seinen hochaffinen Rezeptor, strukturell untersucht. Der molekulare Mechanismus der anschließenden Rekrutierung des niederaffinen Rezeptortyps war bisher nicht bekannt. Die vorliegende Arbeit beschreibt die Präparation, Kristallisation und Strukturaufklärung des ternären Komplexes aus BMP-2 und den extrazellulären Domänen von BMPR-IA und ActR-IIB. Mit der Kristallstruktur dieses ternären Komplexes kann erstmals der Mechanismus der BMP Rezeptoraktivierung von der Bindung des Liganden bis hin zur Transaktivierung untersucht werden. Der Ligand BMP-2 präsentiert sich hier, im Gegensatz zu anderen Mitgliedern der TGF-beta Superfamilie, als nahezu starre Komponente, um welche die beiden Rezeptortypen symmetrisch angelagert werden. Zwischen den extrazellulären Domänen der Rezeptoren können keine direkten Kontakte beobachtet werden. Die in Zellen beobachtete Kooperativität bei der Rekrutierung des niederaffinen Rezeptors im BMP-2 System ist folglich weder durch allosterische Effekte, noch durch direkte Rezeptor-Rezeptor-Kontakte erklärbar. Vielmehr repräsentiert die Bindung des niederaffinen Rezeptors von BMP-2 einen Minimalmechanismus, bei dem Kooperativität über die Verringerung der Freiheitsgrade durch Lokalisation des Liganden in der Zellmembran erzeugt wird. Die durchgeführten Mutations-/Interaktionsanalysen erlauben vertiefende Einblicke wie Affinität und Spezifität im BMP/Activin-System generiert werden. Es zeigt sich, dass sowohl bei der niederaffinen Interaktion von ActR-IIBecd mit BMP-2 bzw. BMP-7 als auch bei der hochaffinen Bindung von ActA mit ActR-IIBecd ein Großteil der freien Bindungsenergie von denselben hydrophoben Interaktionen getragen wird. Während polare Interaktionen bei der niederaffinen Bindung der BMPs an ActR-IIBecd kaum eine Rolle spielen, stellt die zentrale Wasserstoffbrücke zwischen ActA Ser90(OG) und ActR-IIB Leu61(N) bei der Bildung des Komplexes ActA/ActR-IIBecd eine entscheidende Determinante der hochaffinen Bindung dar. BMP-2 bindet an die Typ II Rezeptoren BMPR-II, ActR-II und ActR-IIB mit nahezu identischer Affinität, daher wird eine promiske Verwendung dieser Rezeptoren angenommen. In dieser Arbeit konnte gezeigt werden, dass die spezifische Erkennung und Bindung der Typ II Rezeptoren durch den Austausch einzelner Aminosäuren modulierbar ist. Mit den hier gewonnenen Kenntnissen über den molekularen Mechanismus der Typ II Rezeptorerkennung ist nun eine Generierung von BMPs mit definierter Typ II Rezeptorspezifität möglich. Diese BMP-2 Varianten können als Werkzeuge zur Aufklärung von Typ II Rezeptor-spezifischen Signalwegen verwendet werden. Ebenso wäre es denkbar, BMP-2 Varianten mit ausgeprägter Typ II Rezeptor Spezifität in vivo zur Modulation TypII Rezeptor spezifischer Signalwege zu benutzen. Beispielsweise könnte ein auf BMP-2 basierendes ActR-IIB-spezifisches Protein als Myostatin-Antagonist zur Behandlung von Muskeldystrophie eingesetzt werden.
Automated AFM analysis of DNA bending reveals initial lesion sensing strategies of DNA glycosylases
(2020)
Base excision repair is the dominant DNA repair pathway of chemical modifications such as deamination, oxidation, or alkylation of DNA bases, which endanger genome integrity due to their high mutagenic potential. Detection and excision of these base lesions is achieved by DNA glycosylases. To investigate the remarkably high efficiency in target site search and recognition by these enzymes, we applied single molecule atomic force microscopy (AFM) imaging to a range of glycosylases with structurally different target lesions. Using a novel, automated, unbiased, high-throughput analysis approach, we were able to resolve subtly different conformational states of these glycosylases during DNA lesion search. Our results lend support to a model of enhanced lesion search efficiency through initial lesion detection based on altered mechanical properties at lesions. Furthermore, its enhanced sensitivity and easy applicability also to other systems recommend our novel analysis tool for investigations of diverse, fundamental biological interactions.
Single crystal X-ray studies on bis[3,4,5,6-tetrabromo-1 ,2-benzenediolato(2- )](pyrrolidiniomethyl)silicate acetonitrile solvate [(C6Br40 2hSiCH2(H)NC4H8 · CH3CN; monoclinic, P2t/c, a = 808.5(4), b = 1533.0(8), c = 2212.6(1) pm, ß = 97.67(2)0 , Z = 4] revealed a zwitterionic structure with a pentacoordinate, formally negatively charged silicon atom and a positively charged ammonium moiety. The silicon atom is surrounded by four oxygen atoms and one carbon atom in a trigonalbipyramidal fashion, with the carbon atom in an equatorial position. The structure is displaced by 7.0% from the trigonal bipyramid towards the square pyramid. The zwitterion and the CH3CN molecule form intermolecular N-H · · · N hydrogen bonds.
The title compound, C\(_{12}\)H\(_{9}\)N\(_{3}\)O, is an intermediate in the synthesis of the muscarinic M2 receptor antagonist AFDX-384. The seven-membered ring adopts a boat conformation and the dihedral angle between the planes of the aromatic rings is 41.51 (9)°. In the crystal, molecules are linked into [001] chains of alternating inversion dimers formed by pairs of N-H・・・O hydrogen bonds and pairs of N-H・・・N hydrogen bonds. In both cases, R\(_{2}\)\(^{2}\)(8) loops are generated.
Protein ubiquitination occurs through the sequential formation and reorganization of specific protein-protein interfaces. Ubiquitin-conjugating (E2) enzymes, such as Ube2S, catalyze the formation of an isopeptide linkage between the C-terminus of a “donor” ubiquitin and a primary amino group of an “acceptor” ubiquitin molecule. This reaction involves an intermediate, in which the C-terminus of the donor ubiquitin is thioester-bound to the active site cysteine of the E2 and a functionally important interface is formed between the two proteins. A docked model of a Ube2S-donor ubiquitin complex was generated previously, based on chemical shift mapping by NMR, and predicted contacts were validated in functional studies. We now present the crystal structure of a covalent Ube2S-ubiquitin complex. The structure contains an interface between Ube2S and ubiquitin in trans that resembles the earlier model in general terms, but differs in detail. The crystallographic interface is more hydrophobic than the earlier model and is stable in molecular dynamics (MD) simulations. Remarkably, the docked Ube2S-donor complex converges readily to the configuration seen in the crystal structure in 3 out of 8 MD trajectories. Since the crystallographic interface is fully consistent with mutational effects, this indicates that the structure provides an energetically favorable representation of the functionally critical Ube2S-donor interface.
In the molecular structure of the dinuclear title compound \([η^5-(C_5(CH_3)_5)(CO)Fe{(μ-BCl)(μ-CO)}PtCl(P(C_6H_{11})_3)]·C_6H_6\), the two metal atoms, iron(II) and platinum(II), are bridged by one carbonyl (μ-CO) and one chloridoborylene ligand (μ-BCl). The \(Pt^{II}\) atom is additionally bound to a chloride ligand situated trans to the bridging borylene, and a tricyclohexylphosphane ligand \((PCy_3)\) trans to the carbonyl ligand, forming a distorted square-planar structural motif at the \(Pt^{II}\) atom. The \(Fe_{II}\) atom is bound to a pentamethylcyclopentadienyl ligand \([η^5-C_5(CH_3)_5]\) and one carbonyl ligand (CO), forming a piano-stool structure. Additionally, one benzene solvent molecule is incorporated into the crystal structure, positioned staggered relative to the pentamethylcyclopentadienyl ligand at the \(Fe^{II}\) atom, with a centroid–centroid separation of 3.630 (2) Å.
C\(_{19}\)H\(_{16}\)N\(_2\)OS, triclinic, P (1) over bar (no. 2), a= 8.1510(3) angstrom, b = 8.8021(3) angstrom, c =11.3953(5) angstrom, alpha =72.546(2)degrees, beta=84.568(2)degrees, gamma =80.760(2)degrees, V =768.86(5) angstrom(3), Z =2, R\(_{gt}\)(F) = 0.0491, WR\(_{ref}\)(F-2) = 0.1494, T =100 K.
The title compound, \(C_{19}H_{17}PS_2\), results from the direct deprotonation of diphenylmethylphosphine sulfide and subsequent reaction with diphenyl disulfide. The C-P and C-S bond lengths of 1.8242 (18) and 1.8009 (18) Å, respectively, of the central P-C-S linkage are comparable to those found in the sulfonyl analogue, but are considerably longer than those reported for the dimetallated sulfonyl compound. The dihedral angle between the benzene rings of the diphenylmethyl moiety is 69.46 (7)°. No distinct intermolecular interactions are present in the crystal structure.
The intrahelical salt bridge between \(E/D^{3.49}\) and \(R^{3.50}\) within the E/DRY motif on helix 3 (H3) and the interhelical hydrogen bonding between the E/DRY and residues on H6 are thought to be critical in stabilizing the class A G protein-coupled receptors in their inactive state. Removal of these interactions is expected to generate constitutively active receptors. This study examines how neutralization of \(E^{3.49/6.30}\) in the thromboxane prostanoid (TP) receptor alters ligand binding, basal, and agonist-induced activity and investigates the molecular mechanisms of G protein activation. We demonstrate here that a panel of full and partial agonists showed an increase in affinity and potency for E129V and E240V mutants. Yet, even augmenting the sensitivity to detect constitutive activity (CA) with overexpression of the receptor or the G protein revealed resistance to an increase in basal activity, while retaining fully the ability to cause agonist-induced signaling. However, direct G protein activation measured through bioluminescence resonance energy transfer (BRET) indicates that these mutants more efficiently communicate and/or activate their cognate G proteins. These results suggest the existence of additional constrains governing the shift of TP receptor to its active state, together with an increase propensity of these mutants to agonist-induced signaling, corroborating their definition as superactive mutants. The particular nature of the TP receptor as somehow "resistant" to CA should be examined in the context of its pathophysiological role in the cardiovascular system. Evolutionary forces may have favored regulation mechanisms leading to low basal activity and selected against more highly active phenotypes.
Sodium-glucose transporters (SGLT) belong to the solute carrier 5 family, which is characterized by sodium dependent transport of sugars and other solutes. In contrast, the human SGLT3 (hSGLT3) isoform, encoded by SLC5A4, acts as a glucose sensor that does not transport sugar but induces membrane depolarization by Na\(^{+}\) currents upon ligand binding. Whole-exome sequencing (WES) of several extended pedigrees with high density of attention-deficit/hyperactivity disorder (ADHD) identified a triplet ATG deletion in SLC5A4 leading to a single amino acid loss (ΔM500) in the hSGLT3 protein imperfectly co-segregating with the clinical phenotype of ADHD. Since mutations in homologous domains of hSGLT1 and hSGLT2 were found to affect intestinal and renal function, respectively, we analyzed the functional properties of hSGLT3[wt] and [ΔM500] by voltage clamp and current clamp recordings from cRNA-injected Xenopus laevis oocytes.
The cation conductance of hSGLT3[wt] was activated by application of glucose or the specific agonist 1-desoxynojirimycin (DNJ) as revealed by inward currents in the voltage clamp configuration and cell depolarization in the current clamp mode. Almost no currents and changes in membrane potential were observed when glucose or DNJ were applied to hSGLT3[ΔM500]-injected oocytes, demonstrating a loss of function by this amino acid deletion in hSGLT3. To monitor membrane targeting of wt and mutant hSGLT3, fusion constructs with YFP were generated, heterologously expressed in Xenopus laevis oocytes and analyzed for membrane fluorescence by confocal microscopy. In comparison to hSGLT3[wt] the fluorescent signal of mutant [ΔM500] was reduced by 43% indicating that the mutant phenotype might mainly result from inaccurate membrane targeting. As revealed by homology modeling, residue M500 is located in TM11 suggesting that in addition to the core structure (TM1-TM10) of the transporter, the surrounding TMs are equally crucial for transport/sensor function.
In conclusion, our findings indicate that the deletion [ΔM500] in hSGLT3 inhibits membrane targeting and thus largely disrupts glucose-induced sodium conductance, which may, in interaction with other ADHD risk-related gene variants, influence the risk for ADHD in deletion carriers.